Number 5: The FDA has approved Imuldosa (ustekinumab-srlf), a biosimilar referencing Stelara (ustekinumab), for the treatment of autoimmune diseases such as plaque psoriasis, psoriatic arthritis, ...
Patient-Reported Outcomes Similar Between Adalimumab-adbm, Reference Product in VOLTAIRE-RA Study ...
Biosimilars are safe, effective, and well-tolerated for psoriasis treatment, providing significant cost savings for the ...
A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to ...
BioRationality—The Missing Rationality in Biosimilar Discussions and the Path Forward ...
The European Union's (EU) approach to biosimilars has revolutionized the biopharmaceutical market by driving innovation, ...
During a recent webinar, experts discussed critical regulatory aspects for generics and biosimilars, highlighting strategies ...
Ivo Abraham, PhD, RN, director of the Center for Health Outcomes and PharmacoEconomic Research at the University of Arizona ...
Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.